Beta thalassemia major is rare in Serbia. Previously incurable, affected patients now live to adulthood with regular blood transfusions. The improvement in supportive treatment over recent decades has given rise to many more patients suffering from the associated metabolic complications of anaemia and iron overload, such as osteopenia and other skeletal changes. We present two patients with severe beta thalassemia major from early childhood, who encountered pathological long-bone fractures during the clinical course of their disease. One suffered a distal femoral diaphyseal fracture, and the second a distal tibia fracture. Both fractures occurred in osteopenic bone and were managed non-operatively due to the patients' general medical condition. Despite intense medical intervention, both patients died from disease progression within one year of their fractures, aged 23 and 24 years. As life expectancy rises it is anticipated that an increased number of beta thalassemia major patients will suffer pathological long-bone and other osteoporotic fractures. These fractures appear to both herald and contribute to a general clinical deterioration of this disease. Advances in stem-cell technology may hold the key for a definitive cure.
INTRODUCTION
T halassemia is a genetic disease which affects the production of one or more globin chains (alpha, beta, gamma and delta), resulting in a depletion or loss of hemoglobin function. The disease has several clinical entities including thalassemia minor (a mild heterozygous trait/carrier state), thalassemia intermedia (a severe heterozygous disease), and thalassemia major (homozygous disease), the most severe.
Thalassemia major is most prevalent in people of Mediterranean, Arab and Asian origin. In Serbia the most common disease form is the thalassemia trait, which typically presents with iron resistant microcytic anaemia and occassionally with jaundice. The major form of thalassemia is rare and affects only very few cases per year. After the introduction of typed, filtrated transfusions of packed red blood cells (PRBC) and chelating agents (deferoxamine), the survival of patients improved 1 . However, an increasing number of patients suffer from the secondary metabolic effects of the disease, including osteoporosis and its related fractures [2] [3] [4] [5] .
CASE REPORTS, MATERIAL AND METHODS
First patient, VP born in 1981, was diagnosed with beta thalassemia major and the Lepore hemoglobin variant at the age of 18 months. He was treated with intermittent blood transfusions and subcutaneous deferoxamine infusions, and underwent splenectomy at the age of 9 years. His early childhood development was not significantly affected. In 1999 he was referred to our Institute because of a deteriorating condition. On examination he was found to ha-ve many clinical features of secondary hemosiderosis, including bronze skin hyperpigmentation, hepatomegaly 10 cm below the right costal margin (RCM), hypogonadism, and diabetes. Laboratory analyses demonstrated severe anemia with leukoerythoblastic differential and signs of liver decompensation due to secondary hemosiderosis (AST 95U/L, ALT 60U/L, AP 130U/L, gGT 35U/L, LDH 598U/L) with markedly elevated ferritin 7420 mcg/L (normal limit 500 mcg/L). The patient was commenced on regular transfusions of filtrated PRBC, receiving 3-4 PRBC bags per month, and had several courses of defero-xamine. Withnin 4 years his ferritin levels rised to 8500 mcg/L, with further progression of hepatomegaly (15cm below the RCM); though liver function tests had not deranged further. rezime In August 2004 the patient suffered a spontaneous stress fracture of the distal femoral diaphysis. There had been no prodromal symptoms or prior clinical skeletal problems. The patient had delayed bony union and ongoing pain following conservative management in plaster cast ( Figures  1, 2 ). Radiographs showed rarefaction of the cancellous bone, loss of cortical thickness and widening of the intramedullary canal ( Figure 3 ). Similar osseous changes were also noted in both humeri. The lumbar spine was osteopenic and the L2 vertebra had loss of height.
The patient's condition continued to deteriorate, with a more prominent anemia and increased transfusion demands, with further deterioration in liver function. The patient died in July 2005 at the age of 23 from progressive hepatic failure.
Second patient, ZV born in 1976 had the Yugoslav-defined beta thalassemic homozygous mutation and the Hemoglobin Lepore variant, and was diagnosed with beta thalassemia major at the age of 2. She underwent splenectomy at the age of 16 in an attempt to reduce the number of hemolytic crises, and was included in the 1996 trial with hydroxyurea (350mg/d) and sodium butyrate.
She was referred to our Institute in 2000 at age of 24, with a severe deterioration in her general health, signs of hepatic insufficiency and severe endocrine dysfunction (insulin dependent diabetes mellitus and amenorrhea). The patient had also recently developed severe bony pain in the axial skeleton and in all four limbs from bone marrow hyperplasia (Figure 4) , and had sustained a fracture of the distal tibia immediately prior to hospital admission. The fracture was treated with manipulation and plaster cast immobilization, but failed to show any signs of bony union by 3 months. On admission her Karnofsky index was 30% and ECOG performance was 3. She had severe hemolytic anemia as a part of the thalassemia syndrome with leukoeryhtroblastic differential. Ferritin levels were not determined due to technical reasons, and transferrin saturation was 81%. She also had hepatomegaly 7cm below the RCM, with deranged liver tests, ALT 32U/L, AST 55U/L, AP 97U/L, LDH 650U/L. She developed a deep vein thrombosis in her injured leg shortly after admission, despite thromboprophylaxis, and died from hepatic insufficiency at the age of 24.
Both patients had small stature, and were below the 5 th centile for height. Neither had trophic changes or legs ulcers, or a prior history of skeletal problems, and both had erythroblastosis without particularly marked rises in alkaline phosphatase.
DISCUSSION
The underlying mechanisms of skeletal involvement in thalssemia are complex 5, 6 . Patients suffer hemolysis and subsequent tissue hypoxia, as a result of their globin dysfunction. As other regulatory mechanisms are preserved, patients develop intramedullary bone marrow hyperplasia in reaction to this hypoxia. It is now recommended that patients be transfused to hemoglobin levels of 110-120 g/L to decrease tissue hypoxia and erythropoietin secretion 1, 7, 8 . Splenectomy is also indicated in severe forms of hemolysis.
Hemosiderosis of the hypophysis, pancreas and other organs, secondary to hemolysis and multiple PRBC transfusions, leads to many endocrine and metabolic changes. These endocrine changes affect the process of ossification and lead to delays in bone maturation, premature epiphyseal fusion, a decrease in cortical bone thickness, abnormalities in remodeling and arthralgia 3, 4, 5 . Some have suggested treating thalassemic osteopenia with dietary supp- lements such as 1200mg calcium daily (in the adolescent population), vitamins D, B6, B12, and K together with physical exercise and training 3, 4 . Hormonal treatment (estrogen, testosterone) is indicated where there is hypogonadism, and calcitonin and bisphosphonates when treating osteoporosis 6 . Thalassemia major typically develop enlargement of the centers of ossification of the frontal bones leading to thickening of the skull (caput quadratum), and earlier ossification and premature fusion of the epiphyses, affecting longitudinal growth; the humerus is typically more affected than the femur 9 . The spine is also commonly affected by scoliosis, kyphosis, and osteoporosis. Despite supportive treatment fractures are common affecting around 30% of patients (with 20% suffering multiple fractures) 2 . The femur and tibia are the most affected bones, with two peaks in the incidence of femoral fractures (at 5-12 years and 14-17 years) 8 .
Thalassemia patients with bone pain should undergo radiography. Our patients were found to have typical decreases in the cortical bone thickness, and dilated meta-physes. Patients may also have "punched-out" osteolysis, Erlenmeyer bone deformities, Schmörl nodes and bony deformity angulations and bone shortening (our X-ray of humerus). Fracture lines are generally transverse, and bone scintigraphy and MRI can reveal microfractures, especially around the ankles 9, 10 . Differential diagnoses should also be borne in mind, such as vitamin D resistant rickets, osteomyelitis, leukemia, lymphoma, and metastases.
Fractures in thalassemia major patients are preferably managed non-operatively as the bone is often not strong enough to be accommodate the implants 11 ; obvious exceptions include femoral neck fractures where internal fixation is more appropriate. Though callus formation is unusual, the bone healing time is generally normal or slightly prolonged. This is not the case in patients with severe anemia where delayed union may develop (as was seen in our two patients). Refractures are common, though bone remodeling can be good, and osteotomies can be performed for residual limb deformity. Our patients' long-bone fractures coincided with their general clinical deterioration, and both died of hepatic failure within a year despite intensive supportive care. It thus appears that these fractures may both herald and contribute to a terminal phase in beta thalassemia. It is hoped that the significant morbidity and mortality associated with severe form of this disease will be resolved through advances in stem cell grafting and better other supportive and chelating treatment with new oral agents.
SUMMARY BETA TALASEMIJA. PRIKAZ DVA SLU^AJA SA FRAK-TURAMA DUGIH KOSTIJU
Beta talasemija je retka u Srbiji. Pobolj{anje suportivne terapije u pro{lim decenijama, dovelo je do toga da sve ve}i broj ovih pacijenata ima problem sa udru'enim metaboli~kim komplikacijama anemije i o{te}enja gvo'djem, kao {to su osteopenija i prelomima. Prikazujemo dva pacijenta sa te{kim oblikom beta talasemije, koja je dijagnostikovana u detinjtsvu, a kod kojih je do{lo do patolo{kih preloma dugih kostiju u toku njihove osnovne bolesti. Jedan pacijent je zadobio prelom distalog dela femura, a drugi prelom distalne tibije. Oba preloma su nastala na ostepeni~noj kosti i bili su le~ena neoperativno, zbog op{teg stanja pacijenata. Uprkos intenzivnom le~enju, oba pacijenta su preminula zbog progresije osnovne bolesti, u uzrastu od 23 i 24 godine. Kako se du'ina 'ivota pove}ava, mo'e se zaklju~iti da }e se u budu}nosti pove}avati broj pacijenata sa beta talasemijom kod kojih }e nastajati patolo{ki prelomi dugih kostiju, kao i drugi prelomi zbog osteoporoze. Ovi prelomi su uzrokovani lo{im stanjem pacijenta, ali i dovode i do daljeg klini~kog pogor{anja bolesti. Napredak u tehnologiji mati~nih }elija je klju~za definitivno le~enje ove bolesti.
Klju~ne re~i: beta talasemija maior, osteopenia, frakture dugih kostiju.
BIBLIOGRAPHY

